During a yearlong stay in the United States, one of the things that struck me most was how easy it is to come across television and YouTube advertisements for prescription-only medications—from diabetes and obesity treatments to anticancer drugs and antidepressants. Packed with slick visuals and attractive actors, these commercials rely on the same rapid narration and fine-print disclaimers familiar to viewers of South Korean insurance ads.
Only two countries in the world—the United States and New Zealand—permit direct-to-consumer (DTC) advertising for prescription-only medications. In the U.S., DTC drug advertising has grown into a massive $10 billion-a-year industry. Recently, however, American lawmakers have begun questioning this long-standing system. In 2025, amid bipartisan momentum to curb rising healthcare costs, the "End Prescription Drug Ads Now Act" was introduced in the U.S. Senate to impose a comprehensive ban on DTC prescription drug advertising across all media platforms. The measure is currently under review by the relevant Senate committee.
Supporters: Protecting the Right to Know and Raising Disease Awareness
Is direct-to-consumer prescription drug advertising truly necessary? Proponents argue first and foremost that ads protect patients' right to know while raising public awareness about various medical conditions.
For decades, clinical information remained almost exclusively in the hands of physicians and pharmacists, leaving patients in a passive role where they simply accepted whatever was prescribed. Supporters contend that DTC ads empower patients to recognize that their symptoms may stem from treatable conditions, thereby lowering the psychological barrier to seeking professional care.
Advocates also emphasize the role of advertising in disease education. Commercials can prompt individuals to realize that symptoms easily dismissed as normal aging or fatigue may actually indicate chronic conditions, rare diseases, or autoimmune disorders. Furthermore, studies indicate that advertising has helped destigmatize sensitive conditions such as depression and sexual dysfunction, encouraging more people to seek early diagnosis and treatment. Ultimately, supporters view DTC advertising as a symbolic driver behind the rise of "engaged patients"—individuals who actively research health information and consult their doctors about whether a specific treatment is right for them.
Opponents: Downplaying Risks, Distorting Care, and Driving Up Costs
Opponents take a starkly different stance, arguing that DTC advertising distorts clinical decision-making and artificially inflates healthcare spending.
Because prescription drugs carry potential side effects as significant as their therapeutic benefits, critics argue they should be prescribed strictly under professional medical supervision. However, DTC commercials—often enhanced by flashy visual effects—frequently exaggerate treatment benefits while glossing over high costs, contraindications, and severe side effects in fine print or hurried voiceovers. This can leave consumers with the false impression that a heavily advertised brand-name drug is a universal cure.
Critics also warn that patients influenced by advertising often pressure physicians to prescribe specific, high-priced branded medications. Even when a doctor determines that lifestyle modifications, lower-cost generic equivalents, or alternative therapies would be safer and more cost-effective, valuable clinical time is wasted attempting to persuade patients who have been swayed by marketing.
Furthermore, opponents caution that healthy individuals may begin pathologizing minor, non-critical symptoms, leading to unnecessary clinic visits and overmedication. Over time, this dynamic imposes a heavy financial burden on national healthcare systems while generating outsized profits for pharmaceutical companies.
America’s Trial and Error as a Mirror for Health Policy
In South Korea, direct-to-consumer advertising for prescription drugs remains strictly prohibited. Yet the debate in the U.S. is far from irrelevant. In today's borderless digital environment, South Korean consumers are regularly exposed to unfiltered U.S. drug commercials and health claims through YouTube, social media, and cross-border e-commerce platforms.
Moreover, the influence of U.S. drug advertising is already reaching South Korea's healthcare landscape. Patient advocacy groups increasingly demand faster domestic access to newly advertised therapies, impacting the government's drug-price negotiations with multinational pharmaceutical corporations.
At the same time, attempting to strictly restrict patient access to medical information is no longer practical in the internet age. Rather than relying solely on blanket prohibitions, some experts argue that governments must proactively establish official, public-interest channels and evidence-based guidelines so patients can navigate health information safely.
As the United States reevaluates its policy and considers a total ban on prescription drug ads, South Korea should view America's trial and error as an instructive mirror. Meaningful patient engagement and quality care begin not with slick commercial advertising, but with deep trust between doctors and patients and the transparent disclosure of reliable medical information..
